Preoperative survivin mRNA detection in peripheral blood is an independent predictor of outcome in esophageal carcinoma

Pharmacogenomics

Volumn 11, Issue 3, 2010, Pages 341-347

  Hoffmann, Andreas Claudius ^a   Vallbhmer, Daniel ^b   Grimminger, Peter ^b   Metzger, Ralf ^b   Prenzel, Klaus L ^b   Hoelscher, Arnulf H ^b   Brabender, Jan ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Circulating tumor cells; Esophageal cancer; Outcome; Survivin; SVV

Indexed keywords

MESSENGER RNA; SURVIVIN;

ADULT; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PHARMACOGENETICS; PREOPERATIVE PERIOD; PROGNOSIS; RNA, MESSENGER;

SAL VIEJA VIRUS;

EID: 77949609513     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.164     Document Type: Article

References (45)

1. Holscher AH, Vallböhmer D: [Surgical treatment of esophageal tumors including local ablation]. Zentralbl. Chir. 132(2), W18-W36; quiz W37-W38 (2007).
2. Lordick F, Ott K, Novotny A, Schuhmacher C, Siewert JR: [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences]. Chirurg 78(9), 792-801 (2007).
3. Metzger R, Drebber U, Baldus SE, Monig SP, Holscher AH, Bollschweiler E: Extracapsular lymph node involvement differs between squamous cell and adenocarcinoma of the esophagus. Ann. Surg. Oncol. 16(2), 447-453 (2009).
4. Heitmiller RF: Epidemiology, diagnosis, and staging of esophageal cancer. Cancer Treat. Res. 105, 375-386 (2001).
5. Schneider PM, Baldus SE, Metzger R et al.: Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classifcation. Ann. Surg. 242(5), 684-692 (2005).
6. Wong R, Malthaner R: Esophageal cancer: a systematic review. Curr. Probl. Cancer. 24(6), 297-373 (2000).
7. Stahl M, Oliveira J: Esophageal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 19(Suppl. 2), II21-II22 (2008).
8. Melis M, McLoughlin JM, Dean EM et al.: Correlations between neoadjuvant treatment, anemia, and perioperative complications in patients undergoing esophagectomy for cancer. J. Surg. Res. 153(1), 114-120 (2008).
9. Tsujimoto H, Ono S, Chochi K, Sugasawa H, Ichikura T, Mochizuki H: Preoperative chemoradiotherapy for esophageal cancer enhances the postoperative systemic infammatory response. Jpn. J. Clin. Oncol. 36(10), 632-637 (2006).
10. Smithers BM, Cullinan M, Thomas JM et al.: Outcomes from salvage esophagectomy post defnitive chemoradiotherapy compared with resection following preoperative neoadjuvant chemoradiotherapy. Dis. Esophagus 20(6), 471-477 (2007).
11. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J. Clin. Oncol. 19(2), 305-313 (2001).
12. Swisher SG, Holmes EC, Hunt KK, Doty JE, Zinner MJ, McFadden DW: The role of neoadjuvant therapy in surgically resectable esophageal cancer. Arch. Surg. 131(8), 819-824; discussion 24-25 (1996).
13. Lordick F, Ebert M, Stein HJ: Current treatment approach to locally advanced esophageal cancer: is resection mandatory? Future Oncol. 2(6), 717-721 (2006).
14. Hoffmann AC, Warnecke-Eberz U, Luebke T et al.: Survivin mRNA in peripheral blood is frequently detected and signifcantly decreased following resection of gastrointestinal cancers. J. Surg. Oncol. 95(1), 51-54 (2007).
15. Brabender J, Vallböhmer D, Grimminger P et al.: ERCC1 RNA expression in peripheral blood predicts minor histopathological response to neoadjuvant radio-chemotherapy in patients with locally advanced cancer of the esophagus. J. Gastrointest. Surg. 12(11), 1815-1821 (2008).
16. Reed JC: The survivin saga goes in vivo. J. Clin. Invest. 108(7), 965-969 (2001).
17. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 3(8), 917-921 (1997).
18. Weiss C, von Romer F, Capalbo G et al.: Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 74(5), 1455-1460 (2009).
19. Hsu KF, Lin CK, Yu CP et al.: Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Dis. Esophagus 22(5), 402-408 (2009).
20. Vallböhmer D, Kuhn E, Warnecke-Eberz U et al.: Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 9(6), 681-690 (2008).
21. Sobin LH, Fleming ID: TNM classifcation of malignant tumors, ffth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 80(9), 1803-1804 (1997).
22. Lu KH, Patterson A P, Wang L et al.: Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition ana lysis. Clin. Cancer Res. 10(10), 3291-3300 (2004).
23. Hoffman AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P: A three-gene signature for outcome in soft tissue sarcoma. Clin. Cancer Res. 15(16), 5191-5198 (2009).
24. Hoffmann AC, Mori R, Vallböhmer D et al.: High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia 10(7), 674-679 (2008).
25. Rohatgi PR, Swisher SG, Correa AM et al.: Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int. J. Gastrointest. Cancer 36(2), 69-76 (2005).
26. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH: Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 92(3), 549-555 (2001).
27. Siewert JR, Ott K: Are squamous and adenocarcinomas of the esophagus the same disease? Semin. Radiat. Oncol. 17(1), 38-44 (2007).
28. Khan Z, Tiwari RP, Mulherkar R et al.: Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic fndings. Head Neck 31(8), 1039-1048 (2009).
29. Cohen SJ, Alpaugh RK, Gross S et al.: Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 6(2), 125-132 (2006).
30. Hiraiwa K, Takeuchi H, Hasegawa H et al.: Clinical signifcance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann. Surg. Oncol. 15(11), 3092-3100 (2008).
31. Schwarzenbach H, Alix-Panabieres C, Muller I et al.: Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin. Cancer Res. 15(3), 1032-1038 (2009).
32. Lurje G, Schiesser M, Claudius A, Schneider PM: Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. J. Oncol. 2010, 392652 (2010).
33. Grimminger P, Vallböhmer D, Hoffmann A et al.: Quantitative ana lysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer. J. Surg. Oncol. 100(6), 447-451 (2009).
34. Cao M, Yie SM, Wu SM et al.: Detection of survivin-expressing circulating cancer cells in the peripheral blood of patients with esophageal squamous cell carcinoma and its clinical signifcance. Clin. Exp. Metastasis 26(7), 751-758 (2009).
35. Yie SM, Lou B, Ye SR et al.: Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann. Surg. Oncol. 15(11), 3073-3082 (2008).
36. Yie SM, Lou B, Ye SR et al.: Clinical signifcance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer 63(2), 284-290 (2009).
37. Yie SM, Luo B, Ye NY, Xie K, Ye SR: Detection of survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA. Clin. Exp. Metastasis 23(5-6), 279-289 (2006).
38. Warnecke-Eberz U, Hokita S, Xi H et al.: Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol. Rep. 13(6), 1241-1246 (2005).
39. Klein CA: Cancer. The metastasis cascade. Science 321(5897), 1785-1787 (2008).
40. Ling X, Bernacki RJ, Brattain MG, Li F: Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J. Biol. Chem. 279(15), 15196-15203 (2004).
41. Kim JY, Chung JY, Lee SG et al.: Nuclear interaction of Smac/DIABLO with survivin at G2/M arrest prompts docetaxel-induced apoptosis in DU145 prostate cancer cells. Biochem. Biophys. Res. Commun. 350(4), 949-954 (2006).
42. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR: Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6(1), 29-40 (2004).
43. Beardmore VA, Ahonen LJ, Gorbsky GJ, Kallio MJ: Survivin dynamics increases at centromeres during G2/M phase transition and is regulated by microtubule-attachment and Aurora B kinase activity. J. Cell Sci. 117(Pt 18), 4033-4042 (2004).
44. Ghossein RA, Bhattacharya S, Rosai J: Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin. Cancer Res. 5(8), 1950-1960 (1999).
45. Ghossein RA, Coit D, Brennan M et al.: Prognostic signifcance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. Clin. Cancer Res. 4(2), 419-428 (1998).